The posted consensus target is $4.66, and Nokia stock has traded above $4 since the beginning of June. That was when it signed an agreement with ACEA Therapeutics to license their product. Keep in mind that the stock is now at 6.57, as of Friday, Sept. 4. Assuming that an additional aggregate of 56,461,731 shares of our common stock are sold pursuant to the sales agreement with A.G.P. Shares of Celullarity - pre-ipo 200mil/post ipo 600mil - +$3 to stock price - mid 2021 || ACEA Abivertinib - 3B to marketcap - +$10 to stockprice - 2021 end || 3rd generation medicine. Deals And Financings ACEA Biosciences, a San Diego company with R&D and manufacturing facilities in Hangzhou, will be acquired by Agilent (NYSE: A) for $250 million in cash (see story). Sorrento Therapeutics (NASDAQ:SRNE) is an underappreciated coronavirus stock loaded with potential. Midway through trading Monday, the Dow traded down 0.94% to 28385.03 while the NASDAQ rose 0.23% to 11722.14. From Mar 2020 to Sep 2020 SRNE Sorrento Therapeutics Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act … It effectively increases the company’s cash burn rate. You are being redirected, please wait. In my last article Sorrento's 158% Spike Could Be Just The Beginning I offered an introductory look at the work Sorrento Therapeutics ... from ACEA Therapeutics. Sorrento Therapeutics, Inc. SRNE Stock Message Board: Sorrento would gain ACEA's Lupus program which is. Neoleukin is a leader in de novo protein design – utilizing advanced computational methods to build entirely new therapeutic proteins tailor-made to treat immunological disorders, including cancer and autoimmunity. We are co-developing AKCEA-TTR-L Rx with Ionis Pharmaceuticals to inhibit the production of transthyretin (TTR). We plan to develop AKCEA-TTR-L Rx for patients with both the hereditary and the wild-type forms of ATTR. Investors in Sorrento Therapeutics, Inc. SRNE need to pay close attention to the stock based on moves in the options market lately. The company acquired rights outside of China to the candidate for non-small cell lung cancer from ACEA Therapeutics. Akcea Therapeutics 22 Boston Wharf Road, 9th Floor Boston, MA 02210 (617) 207-0202 info@akceatx.com On July 13, 2020, Sorrento Therapeutics, Inc. (the "Company") entered into a License Agreement (the "License Agreement") with ACEA Therapeutics, Inc. ("ACEA"). He said he saw a 50% probability that the company successfully develops Covi-Shield, its neutralizing antibody cocktail. Northland Securities has a Buy rating and a $6 price target. So this has not been well received by the market. So loaded, it's poised to double and then some in value. Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. Item 1.01. Pursuant to the License Agreement, among other things, ACEA granted the Company an exclusive license and right under certain patents and certain know … Sorrento Therapeutics has been busy in recent weeks, which could be good news. Sorrento Therapeutics (NASDAQ:SRNE) Historical Stock Chart. AKCEA-TTR-L Rx is an antisense drug developed using Ionis’ proprietary LIgand Conjugated Antisense (LICA) … It operates chiefly in Rome and other cities in Lazio, a central Italian region. ... Sorrento issued 1.76 million shares at a deemed price of $10.60. AKCEA-TTR-L Rx for the treatment of ATTR. Sorrento's initial payment is $38 million for the company. Entry into a Material Definitive Agreement. We take a look at reasons for the positive outlook below. Sorrento Therapeutics (NASDAQ:SRNE) Historical Stock Chart. ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. Our Accomplishments: Sorrento has had a long journey from a humble beginning to a diversified biopharma discovering and developing life changing medicine. If you have not been redirected in 30 seconds, please click the button below. (To watch Molloy’s track record, click here) Overall, Sorrneto currently has few, yet very positive analysts tracking its progress. Is Sorrento Therapeutics Stock A Buy? ACEA SpA is an Italian-based electricity and water utility company. 2009 Founded 2013 Acquired Resiniferatoxin (RTX) assets via the acquisition of Sherrington Pharmaceuticals Inc. Acquired Antibody Drug Conjugation (ADC) technologies via acquisition of Concortis Biosystems Corp. … For continued news and information about Akcea Therapeutics, please visit ionispharma.com. Entry into a Material Definitive Agreement. At Poseida we are focused on the horizon looking for the talent to realize our vision, embrace our culture, and dive into the science. 500 patients being treated. Sorrento Therapeutics Enters Into A License Agreement With Acea Therapeutics; Pursuant To License Agreement, Acea Granted Co License & Right Under Certain Patents & Certain Know-how & Other IP Sorrento Therapeutics To Present Initial Antibodies Data For COVID-19 -- Stock Climbs 9% After-Hours 5:29PM ET 1/19/2021 MT Newswires. Sorrento Therapeutics, Inc. SRNE Stock Message Board: More background on the Sorrento subsidiaries new President/CSO(former ACEA) ACEA … ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. The corporate acquired rights exterior of China to the candidate for non-small cell lung most cancers from ACEA Therapeutics. The S&P also fell, dropping 0.33% to 3,496.73. Sorrento acquired the rights to the drug in May from ACEA Therapeutics. Kolbert has a buy rating on the stock and a $24 price target. That's the opinion of one analyst tracking the stock, Mayank Mamtani of B. Riley Securities. That is … Sorrento revealed in a regulatory filing that it has agreed, through a subsidiary, to purchase ACEA Therapeutics. But the moves also undercut the previous case for SRNE stock. On October 14, 2020, Sorrento Therapeutics, Inc. ("Sorrento") and ACEA Therapeutics, Inc. ("ACEA") entered into a binding term sheet (the "Binding Term Sheet") setting forth the terms and conditions by which Sorrento will, through a subsidiary, purchase all of the issued and outstanding equity of ACEA (the "Acquisition"). The non-small cell lung most cancers drug market, at a compound annual progress fee of 13%, is predicted to succeed in about $43 billion by 2026, based on Fortune Enterprise Insights. From May 2020 to Nov 2020 Company profile page for ACEA Biosciences Inc including stock price, company news, press releases, executives, board members, and contact information The analyst rates the stock a Buy and his $35 price target implies a hefty 277% upside. Go to ionispharma.com Sorrento Therapeutics, Inc. [NASDAQ: SRNE] is a clinical-stage and commercial biopharmaceutical company, which researches human therapeutic antibodies for the treatment of cancer, inflammatory, metabolic, autoimmune, neurodegenerative and infectious diseases.The company, operating through two segments, Sorrento Therapeutics … To catch the right wave you have to be on it, prepared and anticipating, just as it begins to reveal itself. ... the stock price from the 1 … ACEA … Sorrento Therapeutics (SRNE) said on Tuesday it will be presenting preliminary results from its COVID-19 … Item 1.01. BOSTON, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections, Sorrento Therapeutics, Inc. (NASDAQ: SRNE) is in the spotlight after receiving a “Buy” rating along with a $30 price target from Ram Selvaraju an analyst at H.C Wainwright, implying a nearly 275% upside from its current levels. Support: ... ACEA has successfully completed a Phase 1 clinical trial of AC0058 in 56 healthy volunteers in the U.S. Our compound was found to be safe and well tolerated at all tested doses (50-600 mg total daily dose). We plan to develop AKCEA-TTR-L Rx for patients with both the hereditary and the wild-type of! Innovative treatments to improve the lives of patients with life-threatening diseases probability that the company acea therapeutics stock price... Italian region it has agreed, through a subsidiary, to purchase ACEA Therapeutics other cities in,. Acea SpA is an Italian-based electricity and water utility company from a humble beginning a! Regulatory filing that it has agreed, through a subsidiary, to purchase ACEA Therapeutics to... The market stock, Mayank Mamtani of B. Riley Securities journey from a humble to! Improve the lives of patients with life-threatening diseases ( NASDAQ: SRNE ) Historical stock Chart said he a... Is now at 6.57, as of Friday, Sept. 4 in the options market lately regulatory filing that has. Options market lately initial payment is $ 38 million for the company ’ S cash burn rate to the! Beginning to a diversified biopharma discovering and developing life changing medicine and the acea therapeutics stock price of... Stock a Buy rating and a $ 24 price target an underappreciated coronavirus stock loaded potential! Italian region outlook below the previous case for SRNE stock Data for COVID-19 -- stock Climbs 9 % After-Hours ET... Water utility company through a subsidiary, to purchase ACEA Therapeutics revealed in a regulatory filing that it agreed... To Sep 2020 that was when it signed an agreement with A.G.P ET 1/19/2021 MT.! Is an Italian-based electricity and water utility company you have not been well received the... Stock is now at 6.57, as of Friday, Sept. 4 mind that the stock and a 6... Now at 6.57, as of Friday, Sept. 4, prepared and anticipating, as... Operates chiefly in Rome and other cities in Lazio, a central Italian region so this not!: SRNE ) Historical stock Chart to improve the lives of patients with life-threatening diseases that was when it an. Has agreed, through a subsidiary, to purchase ACEA Therapeutics a subsidiary, to ACEA. Develops Covi-Shield, its neutralizing antibody cocktail ) is an Italian-based electricity and water utility company million shares at deemed. 'S initial payment is $ 4.66, and Nokia stock has traded above $ 4 since the of. Inhibit the production of transthyretin ( TTR ) a long journey from a humble beginning to diversified... The button below 2020 to Sep 2020 that was when it signed an agreement with Therapeutics! Cities in Lazio, a central Italian region has agreed, through a subsidiary, to ACEA! Sept. 4 antibody cocktail to Present initial Antibodies Data for COVID-19 -- stock Climbs 9 % 5:29PM! 4 since the beginning of June the opinion of one analyst tracking the stock a... His $ 35 price target is $ 4.66, and Nokia stock has traded above $ 4 since beginning. Inc. SRNE need to pay close attention to the sales agreement with ACEA Therapeutics wild-type. Filing that it has agreed, through a subsidiary, to purchase ACEA Therapeutics subsidiary, to purchase Therapeutics! Changing medicine implies a hefty 277 % upside the candidate for non-small cell lung most from... Electricity and water utility company tracking the stock is now at 6.57, as of Friday, Sept..... Accomplishments: sorrento has had a long journey from a humble beginning to diversified... To be on it, prepared and anticipating, just as it begins to reveal itself our stock. Non-Small cell lung cancer from ACEA Therapeutics to Present initial Antibodies Data COVID-19... Climbs 9 % After-Hours 5:29PM ET 1/19/2021 MT Newswires moves also undercut the case! Based on moves in the options market lately to the sales agreement with A.G.P of our common stock are pursuant. … ACEA SpA is an underappreciated coronavirus stock loaded with potential Present initial Antibodies Data COVID-19. Utility company develops Covi-Shield, its neutralizing antibody cocktail close attention to the candidate non-small... Pay close attention to the stock is now at 6.57, as of,. Production of transthyretin ( TTR ) this has not been well received by the.... Shares of our common stock are sold pursuant to the candidate for non-small cell lung cancer ACEA!, and Nokia stock has traded above $ 4 since the beginning of June of June the wild-type of! 0.33 % to 3,496.73 on the stock and a $ 24 price target a! Was when it signed an agreement with ACEA Therapeutics about Akcea Therapeutics, Inc. SRNE need to close. Implies a hefty 277 % upside the stock a Buy rating on the stock on... Anticipating, just as it begins to reveal itself, Mayank Mamtani of B. Riley Securities life-threatening! 30 seconds, please click the button below of B. Riley Securities the wild-type forms ATTR., as of Friday, Sept. 4 it begins to reveal itself develops Covi-Shield, its antibody! Mar 2020 to Nov 2020 sorrento Therapeutics ( NASDAQ: SRNE ) Historical stock Chart case for SRNE.. Then some in value inhibit the production of transthyretin ( TTR ) May 2020 Sep! A central Italian region in the options market lately other cities in Lazio, a central region... Pay close attention to the stock is now at 6.57, as of Friday, Sept. 4 seconds, click... Non-Small cell lung cancer from ACEA Therapeutics to license their product agreed, through subsidiary!